BioCentury | Mar 25, 2021
Management Tracks

Galapagos promotes Filius to president, Litchfield named Merck CFO; plus moves at LianBio, Adverum, Fulcrum, Aptose, Cyclerion, Medigene, Apie and more

...its virus-like particle conjugation technology: a Phase III study in choroidal melanoma, an ocular cancer. La Jolla Institute for Immunology hired...
...trials. BC Staff Merck & Co. Inc. Adverum Biotechnologies Inc. Fulcrum Therapeutics Inc. Aptose Biosciences Inc. Cyclerion Therapeutics Inc. Medigene AG Apie Therapeutics Inc. La Jolla Institute for Immunology Aura...
BioCentury | Jan 20, 2021
Product Development

Gritstone sending a mixed-modality COVID vaccine to Phase I

...epitopes include validated ones licensed from the La Jolla Institute for Immunology...
...antigen Sandi Wong Gritstone Oncology Inc. Bill & Melinda Gates Foundation La Jolla Institute for Immunology National...
BioCentury | Jun 30, 2020
Finance

June 29 Quick Takes: BioNTech pockets $250M; plus three biotechs join NASDAQ IPO queue

...cell therapy development. In March, the company launched a consortium with Vanderbilt University Medical Center, La Jolla Institute for Immunology...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

...candidate mAbs and the spike protein are conducted in the lab of CoVIC leader and La Jolla Institute for Immunology...
...SARS-CoV-2 spike protein Karen Tkach Tuzman, Associate Editor Johnson & Johnson Tulane University School of Medicine Scripps Research Evotec SE La Jolla Institute for Immunology Janssen...
BioCentury | May 26, 2020
Product Development

Understanding and weaponizing immune responses to COVID-19

...for therapeutic indications as opposed to prevention by vaccination,” Alter said. A third presentation from La Jolla Institute for Immunology...
BioCentury | Mar 28, 2020
Translation in Brief

17 FDA-approved drugs show activity against SARS-CoV-2; two groups seek COVID-19 patient-derived mAbs; plus NYU, Scholar Rock and LIfT-King's College

...launched on Wednesday the Global Emerging Pathogen Antibody Discovery Consortium with Vanderbilt University Medical Center, La Jolla Institute for Immunology...
...Inc. New York University Langone Medical Center University of Maryland LIfT BioSciences Ltd. King's College London Vanderbilt University Medical Center Emory University La Jolla Institute for Immunology Coronavirus...
BioCentury | Mar 7, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2019

...in CAR T cells could help treat melanoma, colorectal cancer and other solid tumor types La Jolla Institute for Immunology...
BioCentury | Mar 5, 2019
Distillery Therapeutics

Inhibiting NR4A1, NR4A2 and N4RA3 in CAR Ts to enhance efficacy in solid tumors

...Chen, J. et al. Nature ; published online Feb. 27, 2019 doi:10.1038/s41586-019-0985-x CONTACT: Joyce Chen, La Jolla Institute for Immunology...
...same affiliation as above e-mail: ScottBrownej@njhealth.org CONTACT: Anjana Rao, same affiliation as above e-mail: arao@lji.org Sandi Wong La Jolla Institute for Immunology Nuclear...
BioCentury | Feb 28, 2019
Preclinical News

Removing genes from CAR Ts to improve efficacy, safety

...enter a state of exhaustion upon chronic antigen stimulation. In a Nature letter published Wednesday, La Jolla Institute for Immunology...
...group A member 2; NR4A3 - Nuclear receptor subfamily 4 group A member 3 Sandi Wong Cellectis S.A. La Jolla Institute for Immunology Granulocyte...
BioCentury | Nov 17, 2018
Preclinical News

Spotlight co-founder uses CRISPR screen to ID T cell regulator genes for cancer

...IP from UCSF related to the paper. In a second Cell paper , researchers from La Jolla Institute for Allergy & Immunology...
...expression, and suggest the database could connect gene variants with diseases in different immune cells. Mark Zipkin La Jolla Institute for Immunology Spotlight...
Items per page:
1 - 10 of 52
BioCentury | Mar 25, 2021
Management Tracks

Galapagos promotes Filius to president, Litchfield named Merck CFO; plus moves at LianBio, Adverum, Fulcrum, Aptose, Cyclerion, Medigene, Apie and more

...its virus-like particle conjugation technology: a Phase III study in choroidal melanoma, an ocular cancer. La Jolla Institute for Immunology hired...
...trials. BC Staff Merck & Co. Inc. Adverum Biotechnologies Inc. Fulcrum Therapeutics Inc. Aptose Biosciences Inc. Cyclerion Therapeutics Inc. Medigene AG Apie Therapeutics Inc. La Jolla Institute for Immunology Aura...
BioCentury | Jan 20, 2021
Product Development

Gritstone sending a mixed-modality COVID vaccine to Phase I

...epitopes include validated ones licensed from the La Jolla Institute for Immunology...
...antigen Sandi Wong Gritstone Oncology Inc. Bill & Melinda Gates Foundation La Jolla Institute for Immunology National...
BioCentury | Jun 30, 2020
Finance

June 29 Quick Takes: BioNTech pockets $250M; plus three biotechs join NASDAQ IPO queue

...cell therapy development. In March, the company launched a consortium with Vanderbilt University Medical Center, La Jolla Institute for Immunology...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

...candidate mAbs and the spike protein are conducted in the lab of CoVIC leader and La Jolla Institute for Immunology...
...SARS-CoV-2 spike protein Karen Tkach Tuzman, Associate Editor Johnson & Johnson Tulane University School of Medicine Scripps Research Evotec SE La Jolla Institute for Immunology Janssen...
BioCentury | May 26, 2020
Product Development

Understanding and weaponizing immune responses to COVID-19

...for therapeutic indications as opposed to prevention by vaccination,” Alter said. A third presentation from La Jolla Institute for Immunology...
BioCentury | Mar 28, 2020
Translation in Brief

17 FDA-approved drugs show activity against SARS-CoV-2; two groups seek COVID-19 patient-derived mAbs; plus NYU, Scholar Rock and LIfT-King's College

...launched on Wednesday the Global Emerging Pathogen Antibody Discovery Consortium with Vanderbilt University Medical Center, La Jolla Institute for Immunology...
...Inc. New York University Langone Medical Center University of Maryland LIfT BioSciences Ltd. King's College London Vanderbilt University Medical Center Emory University La Jolla Institute for Immunology Coronavirus...
BioCentury | Mar 7, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2019

...in CAR T cells could help treat melanoma, colorectal cancer and other solid tumor types La Jolla Institute for Immunology...
BioCentury | Mar 5, 2019
Distillery Therapeutics

Inhibiting NR4A1, NR4A2 and N4RA3 in CAR Ts to enhance efficacy in solid tumors

...Chen, J. et al. Nature ; published online Feb. 27, 2019 doi:10.1038/s41586-019-0985-x CONTACT: Joyce Chen, La Jolla Institute for Immunology...
...same affiliation as above e-mail: ScottBrownej@njhealth.org CONTACT: Anjana Rao, same affiliation as above e-mail: arao@lji.org Sandi Wong La Jolla Institute for Immunology Nuclear...
BioCentury | Feb 28, 2019
Preclinical News

Removing genes from CAR Ts to improve efficacy, safety

...enter a state of exhaustion upon chronic antigen stimulation. In a Nature letter published Wednesday, La Jolla Institute for Immunology...
...group A member 2; NR4A3 - Nuclear receptor subfamily 4 group A member 3 Sandi Wong Cellectis S.A. La Jolla Institute for Immunology Granulocyte...
BioCentury | Nov 17, 2018
Preclinical News

Spotlight co-founder uses CRISPR screen to ID T cell regulator genes for cancer

...IP from UCSF related to the paper. In a second Cell paper , researchers from La Jolla Institute for Allergy & Immunology...
...expression, and suggest the database could connect gene variants with diseases in different immune cells. Mark Zipkin La Jolla Institute for Immunology Spotlight...
Items per page:
1 - 10 of 52